INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a cost-effectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to pr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-10-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2001-6689/12/4/23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846104168470675456 |
|---|---|
| author | Mouna Jameleddine Nabil Harzallah Hela Grati Marie Christine Odabachian Jebali Jaafar Chemli Sebastián García Martí Natalie Soto Andrés Pichon-Riviere Chokri Hamouda |
| author_facet | Mouna Jameleddine Nabil Harzallah Hela Grati Marie Christine Odabachian Jebali Jaafar Chemli Sebastián García Martí Natalie Soto Andrés Pichon-Riviere Chokri Hamouda |
| author_sort | Mouna Jameleddine |
| collection | DOAJ |
| description | The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a cost-effectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia’s compulsory insurance scheme. Our analysis was based on a probabilistic Markov cohort model that calculated the costs and quality-adjusted life years (QALY) associated with vemurafenib compared to the standard of care from a public payer perspective. The CEA indicated that vemurafenib provides a gain of 0.38 life years (1.78 vs. 1.4) for an incremental cost of USD 101,106.62 from the perspective of the main public payer (CNAM). This study revealed an incremental cost-effectiveness ratio (ICER) of 163,311.40 USD/QALY and 163,911.46 USD/QALY, respectively, from the CNAM and public health facilities’ perspectives. Vemurafenib cannot be considered cost-effective in terms of what has normally been considered a reasonable willingness to pay (WTP) in Tunisia. A significant price reduction would be necessary to bring the incremental cost-effectiveness ratio to an acceptable level. |
| format | Article |
| id | doaj-art-bc524a3e3cba451589998b4f4e76cafb |
| institution | Kabale University |
| issn | 2001-6689 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-bc524a3e3cba451589998b4f4e76cafb2024-12-27T14:32:43ZengTaylor & Francis GroupJournal of Market Access & Health Policy2001-66892024-10-0112429430510.3390/jmahp12040023INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in TunisiaMouna Jameleddine0Nabil Harzallah1Hela Grati2Marie Christine Odabachian Jebali3Jaafar Chemli4Sebastián García Martí5Natalie Soto6Andrés Pichon-Riviere7Chokri Hamouda8The National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, TunisiaThe National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, TunisiaThe National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, TunisiaThe National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, TunisiaThe National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, TunisiaInstitute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires 1414, ArgentinaInstitute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires 1414, ArgentinaInstitute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires 1414, ArgentinaThe National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, TunisiaThe Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a cost-effectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia’s compulsory insurance scheme. Our analysis was based on a probabilistic Markov cohort model that calculated the costs and quality-adjusted life years (QALY) associated with vemurafenib compared to the standard of care from a public payer perspective. The CEA indicated that vemurafenib provides a gain of 0.38 life years (1.78 vs. 1.4) for an incremental cost of USD 101,106.62 from the perspective of the main public payer (CNAM). This study revealed an incremental cost-effectiveness ratio (ICER) of 163,311.40 USD/QALY and 163,911.46 USD/QALY, respectively, from the CNAM and public health facilities’ perspectives. Vemurafenib cannot be considered cost-effective in terms of what has normally been considered a reasonable willingness to pay (WTP) in Tunisia. A significant price reduction would be necessary to bring the incremental cost-effectiveness ratio to an acceptable level.https://www.mdpi.com/2001-6689/12/4/23vemurafenibadvanced melanomatargeted therapyBRAF V600cost-effectivenesscost utility |
| spellingShingle | Mouna Jameleddine Nabil Harzallah Hela Grati Marie Christine Odabachian Jebali Jaafar Chemli Sebastián García Martí Natalie Soto Andrés Pichon-Riviere Chokri Hamouda INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia Journal of Market Access & Health Policy vemurafenib advanced melanoma targeted therapy BRAF V600 cost-effectiveness cost utility |
| title | INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia |
| title_full | INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia |
| title_fullStr | INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia |
| title_full_unstemmed | INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia |
| title_short | INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia |
| title_sort | ineas s cost effectiveness analysis of vemurafenib paving the way for value based pricing in tunisia |
| topic | vemurafenib advanced melanoma targeted therapy BRAF V600 cost-effectiveness cost utility |
| url | https://www.mdpi.com/2001-6689/12/4/23 |
| work_keys_str_mv | AT mounajameleddine ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT nabilharzallah ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT helagrati ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT mariechristineodabachianjebali ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT jaafarchemli ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT sebastiangarciamarti ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT nataliesoto ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT andrespichonriviere ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia AT chokrihamouda ineasscosteffectivenessanalysisofvemurafenibpavingthewayforvaluebasedpricingintunisia |